Clinical Trials Browser

Phase 1/2 × Recruiting × revumenib × Clear all

NCT06284486 2026-04-13

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04065399 2026-03-18

AUGMENT-101

Phase 1/2 Recruiting

447 enrolled 6 FDA

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07356154 2026-01-21

A Study of Revumenib and Mezigdomide in People With Leukemia

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma